Saturday, April 14, 2018
7:30 AM - 2:30 PM
DoubleTree by Hilton Philadelphia Center City
237 South Broad Street
Philadelphia, PA 19107
Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.
HMS aims to provide important educational updates from leading experts on conditions that are commonly encountered by healthcare providers practicing in the hospital-setting, including chronic obstructive pulmonary disease, diabetes, hepatic encephalopathy, and invasive fungal infections. Now is a critical time for practitioners to align their practices in anticipation of current and future changes in healthcare policy that will affect payment for services in this setting.
Going Green Initiative
In an effort to conserve and reduce the use of paper, participant materials for HMS will only be available electronically. Participants are encouraged to bring their laptops, tablets, or other wifi-enabled mobile devices. Wireless high-speed internet will be provided free of charge.
7:30 AM – 8:00 AM Registration/Breakfast
8:00 AM – 9:00 AM Keynote: Determining the Value in Healthcare
Alpesh Amin, MD
9:00 AM – 10:15 AM Improving Health Outcomes in COPD: Hospital-based Strategies for Optimizing Maintenance Therapy and Promoting Patient Self-management
Gerard J. Criner, MD, FACP, FACCP
10:15 AM – 10:30 AM Break
10:30 AM – 11:45 PM Addressing Challenges to Optimal Diagnosis and Treatment of Invasive Fungal Infections
Peter G. Pappas, MD, FACP
11:45 AM – 12:00 PM Lunch Served
12:00 PM – 1:15 PM Individualizing Management of T2DM in the Hospital Setting to Reduce Macro and Microvascular Complications
Robert J. Chilton, DO, FACC
1:15 PM – 2:30 PM Optimizing Outcomes of Patients Hospitalized for Hepatic Encephalopathy: Focus on Early Intervention and Transitional Care
Alpesh Amin, MD
2:30 PM Closing Remarks
This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
- Define value in healthcare and describe an approach for its assesment in the hospital setting
- Employ innovative in-hospital opportunities to achieve greater value in healthcare
- Discuss the central components of an effective value-based payment model
Chronic Obstructive Pulmonary Disease (COPD) Session
Invasive Fungal Infections (IFIs) Session
- Utilize long-term treatment strategies to reduce hospital readmissions for COPD exacerbations
- Review the clinical evidence regarding the efficacy and safety of long-acting maintenance regimens for COPD
- Select medication delivery devices for patients with COPD based upon individual physical and cognitive characteristics
- Outline a transitional care plan that promotes patient self-management to reduce the risk for future exacerbations and hospital readmissions
- Identify challenges in the diagnosis of common IFIs and recognize clinical circumstances that require empirical treatment
- Review the emerging patterns and underlying mechanisms of fungal resistance
- Employ current guideline recommendations for the treatment of IFIs
Type 2 Diabetes Mellitus (T2DM) Session
- Summarize the correlation between uncontrolled T2DM, its macro and microvascular complications, and associated hospitalizations
- Evaluate the risk/benefit profiles of novel T2DM therapies in achieving glycemic control and in reducing vascular complications
- Employ evidence-based strategies to individualize treatment for diverse patients with T2DM to achieve glycemic control and reduce hospitalizations from vascular complications
Hepatic Encephalopathy (HE) Session
- Describe an approach to the early diagnosis of patient with HE that is consistent with current guideline recommendations
- Summarize clinical trial data on the efficacy and safety of options for acute treatment and prophylaxis of HE
- Implement a transitional care plan to prevent future hospitalizations among patients with HE
A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live event.
Physician Continuing Education
Physician Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, these activitiese have been planned and implemented by the Postgraduate Institute for Medicine and Integrity Continuing Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates these continuing education activities for a total of 6.0 contact hour(s) (0.60 CEUs) of the Accreditation Council for Pharmacy Education.
Hospital Medicine Summit Universal Activity Numbers
Keynote: JA4008162-9999-18-014-L04-P (Application)
COPD: JA4008162-9999-18-009-L01-P (Application)
IFI: JA4008162-9999-18-012-L01-P (Knowledge)
T2DM: JA4008162-9999-18-013-L01-P (Application)
HE: JA4008162-9999-18-041-L01-P (Application)
Instructions to Receive Credit
Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required. Upon receipt of the completed activity evaluation form, you will receive an email from CEcertificate@pimed.com within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.
Nursing Continuing Education
The maximum number of hours awarded for these Continuing Nursing Education activities is 6.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
For information about ACPE or ANCC accreditation of this activity, please contact PIM at (303) 799-1930 or email@example.com.
Americans with Disabilities Act
Event staff will be glad to assist you. Please contact Integrity Continuing Education prior to the live event at (855) 835-4004.
Disclosure of Conflicts of Interest (COI)
Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a provider relative to diagnostic and treatment options of a specific patient's medical condition.
This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is co-provided by Postgraduate Institute for Medicine and Integrity Continuing Education.
This activity is supported by independent educational grants from Astellas Pharma US, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Lilly, Salix, a division of Valeant Pharmaceuticals North America LLC, and Sunovion Pharmaceuticals, Inc.